Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Ann Oncol. 2018 Aug 1;29(8):1687-1700. doi: 10.1093/annonc/mdy167.
The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following 'ultra-high-risk' situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.
欧洲肿瘤内科学会（ESMO）恶性淋巴瘤共识会议于 2015 年 6 月 20 日在瑞士卢加诺举行，会议包括了 25 位领先的多学科专家组成的小组。会议的目的是制定关于难以在 ESMO 临床实践指南中详细考虑的关键主题的建议。确定了以下领域：（1）老年患者，（2）适合临床使用的预后因素和（3）“超高风险”组。在会议之前，专家小组分为三个工作组；每个小组都专注于其中一个领域，以解决与该主题相关的临床相关问题。所有相关的科学文献都由专家事先进行了回顾。在共识会议期间，每个工作组都制定了针对其小组提出的每个问题的建议。然后将这些建议提交给整个多学科小组，达成共识。本文提出了有关以下“超高风险”情况的管理建议：（1）弥漫性大 B 细胞淋巴瘤的早期中枢神经系统复发，（2）原发性难治性霍奇金淋巴瘤和（3）浆母细胞淋巴瘤。本文详细介绍了支持每项建议的证据总结结果。所有专家小组成员都批准了这篇最终文章。
